Imperative Care Raises $100 Million in Debt Financing
Imperative Care, a Campbell, California-based medical technology company, has successfully raised $100 million through a debt financing round. The round was led by Elevage Medical Technologies, with participation from investors such as Perceptive Advisors, Catalio Capital Management, Longaeva Partners, Brown Advisory, Ally Bridge Group, and Bain Capital Life Sciences.
Imperative Care is dedicated to accelerating the development of life-changing technologies that aim to provide more care to patients suffering from stroke and other severe vascular diseases. The company has made significant strides in treating thromboembolic diseases, which are caused by blood clot formation inside veins and arteries.
Investor Details
The financing round was notably led by Elevage Medical Technologies, marking their first involvement with Imperative Care. Perceptive Advisors also co-led the round, while existing investors such as Catalio Capital Management, Ally Bridge Group, and Bain Capital Life Sciences continued their support. New investors Longaeva Partners and Brown Advisory joined the round, indicating growing interest in Imperative Care's mission and technology.
Company Offerings
Imperative Care has a range of commercially available products designed to address thromboembolic diseases. These include the Zoom Stroke System, the Symphony Thrombectomy System, and the Prodigy Thrombectomy System. In addition to these products, the company is developing the Telos robotic platform, an endovascular robotic system aimed at enhancing precision and standardization in medical procedures, thereby expanding access to lifesaving treatments.
Strategic Use of Funds
While specific uses for the newly raised $100 million were not detailed, such significant funding typically supports product development and commercialization efforts. Given Imperative Care's focus, the funds are likely to be directed towards advancing their current product line and further developing the Telos robotic platform. This would align with their goal of improving treatment options for patients with life-threatening vascular diseases.
Conclusion
The successful closure of this $100 million financing round underscores the confidence that investors have in Imperative Care's mission and technological advancements. With strong backing from both new and existing investors, the company is well-positioned to continue its efforts to bring innovative medical solutions to patients in need.